Brief Report: Circulating Cytokine Profiles and Antineutrophil Cytoplasmic Antibody Specificity in Patients With Antineutrophil Cytoplasmic Antibody–Associated Vasculitis

To evaluate circulating cytokine profiles in patients with antineutrophil cytoplasmic antibody–associated vasculitis (AAV), classified by antineutrophil cytoplasmic antibody (ANCA) specificity (proteinase 3 ANCA [PR3‐ANCA] versus myeloperoxidase ANCA [MPO‐ANCA]) or by clinical diagnosis (granulomatosis with polyangiitis [GPA] versus microscopic polyangiitis [MPA]).

[1]  D. Metze,et al.  Nomenclature of cutaneous vasculitides – German translation of the dermatologic addendum to the 2012 Revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides , 2018, Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG.

[2]  J. Pers,et al.  Identification and phenotyping of circulating autoreactive proteinase 3-specific B cells in patients with PR3-ANCA associated vasculitis and healthy controls. , 2017, Journal of autoimmunity.

[3]  D. Cornec,et al.  ANCA-associated vasculitis — clinical utility of using ANCA specificity to classify patients , 2016, Nature Reviews Rheumatology.

[4]  D. Schroeder,et al.  Factors Determining the Clinical Utility of Serial Measurements of Antineutrophil Cytoplasmic Antibodies Targeting Proteinase 3 , 2016, Arthritis & rheumatology.

[5]  P. Merkel,et al.  Clinical outcomes of treatment of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis based on ANCA type , 2015, Annals of the rheumatic diseases.

[6]  C. Doglioni,et al.  Interleukin-6 in ANCA-associated vasculitis: Rationale for successful treatment with tocilizumab. , 2015, Seminars in arthritis and rheumatism.

[7]  J. Levy,et al.  Long-term outcome of anti-neutrophil cytoplasm antibody-associated glomerulonephritis: evaluation of the international histological classification and other prognostic factors. , 2015, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[8]  C. Kallenberg,et al.  Efficacy of remission-induction regimens for ANCA-associated vasculitis. , 2013, The New England journal of medicine.

[9]  L. Rönnblom,et al.  The interferon signature in autoimmune diseases , 2013, Current opinion in rheumatology.

[10]  Panos Deloukas,et al.  Genetically distinct subsets within ANCA-associated vasculitis. , 2012, The New England journal of medicine.

[11]  J. Krischer,et al.  Circulating markers of vascular injury and angiogenesis in antineutrophil cytoplasmic antibody-associated vasculitis. , 2011, Arthritis and rheumatism.

[12]  J. Krischer,et al.  Serum proteins reflecting inflammation, injury and repair as biomarkers of disease activity in ANCA-associated vasculitis , 2011, Annals of the rheumatic diseases.

[13]  P. Merkel,et al.  Rituximab versus cyclophosphamide for ANCA-associated vasculitis. , 2010, The New England journal of medicine.

[14]  Jianwen Cai,et al.  Predictors of Relapse and Treatment Resistance in Antineutrophil Cytoplasmic AntibodyAssociated Small-Vessel Vasculitis , 2005, Annals of Internal Medicine.

[15]  P. Merkel,et al.  A disease-specific activity index for Wegener's granulomatosis: modification of the Birmingham Vasculitis Activity Score. International Network for the Study of the Systemic Vasculitides (INSSYS). , 2001, Arthritis and rheumatism.

[16]  C. Kallenberg,et al.  Toll-like receptor 9 activation enhances B cell activating factor and interleukin-21 induced anti-proteinase 3 autoantibody production in vitro. , 2016, Rheumatology.

[17]  P. Merkel,et al.  2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. , 2013, Arthritis and rheumatism.

[18]  R. Panush.  Rituximab versus cyclophosphamide for ANCA-associated vasculitis , 2011 .